• University of Michigan Health System. Allergic rhinitis. Ann Arbor (MI): University of Michigan Health System (UMHS); 2007 Oct. 12 p. [3 references]

This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. Allergic rhinitis. Ann Arbor (MI): University of Michigan Health System; 2002 Jul. 12 p. [3 references]

Note from the National Guideline Clearinghouse (NGC): The following key points summarize the content of the guideline. Refer to the full text for additional information, including detailed information on dosing, possible side effects, and cost of medications; avoidance of allergens; skin testing; immunological therapy; and considerations for special patient populations (i.e., pediatrics, pregnant patients, patients with severe asthma or severe atopic dermatitis). Definitions for the levels of evidence (A, B, C, D) are provided at the end of the "Major Recommendations" field.

Diagnosis

Allergic rhinitis is an antigen-mediated inflammation of the nasal mucosa that may extend into the paranasal sinuses. Diagnosis is usually made by history and examination ("itchy, running, sneezy, stuffy"). A symptom diary and a trial of medication may be helpful to confirm a diagnosis. Allergy testing is not commonly needed to make the diagnosis, but may be helpful for patients with multiple potential allergen sensitivities.

Therapy

The goal of therapy is to relieve symptoms.

1. Avoidance of allergens is the first step in this process. (Refer to text in the original guideline document for details.) If avoidance fails:
2. The over-the-counter (OTC), non-sedating antihistamine loratadine (Claritin) should be tried initially, as it will provide relief in most cases. If symptoms persist, consider the following options:
3. Prescribed medications
   • Intranasal corticosteroids are considered the most potent medications available for treating allergic rhinitis [A]. They control itching, sneezing, rhinorrhea, and stuffiness in most patients, but do not alleviate ocular symptoms. They have a relatively good long-term safety profile. University of Michigan Health System (UMHS) preferred intranasal corticosteroids for adults are generics: fluticasone (Flonase) and flunisolide (Nasarel). Mometasone (Nasonex AQ) is preferred for children.
   • Oral, non-sedating antihistamines prevent and relieve itching, sneezing, and rhinorrhea, but tend to be less effective for nasal congestion [A]. UMHS preferred prescription antihistamine is fexofenadine (Allegra).
   • Oral decongestants decrease swelling of the nasal mucosa which, in turn, alleviates nasal congestion [A]. However, they are associated with appreciable side effects, especially in geriatric patients, and should only be considered when congestion is not controlled by other agents. They are contraindicated with monoamine oxidase inhibitors (MAOIs), in uncontrolled hypertension and in severe coronary artery disease.
   • Leukotriene inhibitors are less effective than intranasal corticosteroids [A] but may be considered for patients that cannot tolerate the first line agents or have co-morbid asthma.
   • Intranasal cromolyn (OTC) is less effective than intranasal corticosteroids [A]. Cromolyn is a good alternative for patients who are not candidates for corticosteroids. It is most effective when used regularly prior to the onset of allergic symptoms.
   • Intranasal antihistamines (Astelin), while effective in treating the nasal symptoms associated with seasonal and perennial rhinitis and nonallergic vasomotor rhinitis, offer no therapeutic benefit over conventional treatment [A].
   • Ocular preparations should be considered for patients with allergic conjunctivitis who are not adequately controlled with or can not tolerate an oral antihistamine.

Referral

Appropriate criteria for referral to a colleague who specializes in the diagnosis and treatment of allergies may include [D]:

• Consideration of allergy skin/radioallergosorbent test (RAST) testing for better allergen identification for avoidance and/or immunotherapy, because of:
  • Failure of medical therapy.
  • Perennial or seasonal allergic rhinitis that is moderate to severe
• Associated comorbidities (see Table 5 in the original guideline document)
• Any severe allergic reactions causing patient or parental anxiety

Controversial Issues

Medication Versus Immunotherapy

A formal risk/cost-benefit analysis of medication therapy versus immunotherapy (allergy shots) has not been performed; however, patients with moderate to severe symptoms that continue year round (seasonal or perennial allergic rhinitis) may benefit most from immunotherapy [D].

Definitions:

Levels of Evidence

Levels of evidence reflect the best available literature in support of an intervention or test.

1. Randomized controlled trials
2. Controlled trials, no randomization
3. Observational trials
4. Opinion of expert panel

A clinical algorithm for treatment of allergic rhinitis is available in the original guideline document.

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

Conclusions were based on prospective randomized clinical trials if available, to the exclusion of other data; if randomized controlled trials were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.

• University of Michigan Health System. Allergic rhinitis. Ann Arbor (MI): University of Michigan Health System (UMHS); 2007 Oct. 12 p. [3 references]

Not applicable: The guideline was not adapted from another source.

2002 July (revised 2007 Oct)

University of Michigan Health System - Academic Institution

University of Michigan Health System

Allergic Rhinitis Guideline Team

Team Leader: David A. DeGuzman, MD, General Medicine

Team Members: Catherine M. Bettcher, MD, Family Medicine; R. Van Harrison, PhD, Medical Education; Christine L. Holland, MD, Allergy; Cary E. Johnson, PharmD, Pharmacy; Sharon Kileny, MD, Pediatrics; Jeffery E. Terrell, MD, Otolaryngology

UMHS Guidelines Oversight Team: Connie Standiford, MD; William E. Chavey, MD; Van Harrison, PhD

The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.

Team Member; Company; Relationship

David DeGuzman, MD (None)

Catherine Bettcher, MD (None)

R. Van Harrison, PhD (None)

Christine Holland, MD (None)

Cary Johnson, PharmD (None)

Sharon Kileny, MD (None)

Jeffery Terrell, MD, Neilmed, Research support (saline solution)

This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. Allergic rhinitis. Ann Arbor (MI): University of Michigan Health System; 2002 Jul. 12 p. [3 references]

This NGC summary was completed by ECRI on January 7, 2003. The information was verified by the guideline developer on February 4, 2003. This NGC summary was updated by ECRI Institute on January 22, 2008. The updated information was verified by the guideline developer on February 11, 2008.

This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).